Jardiance Generic (Empagliflozin): Availability, Uses, Benefits, Safety, and Cost in 2026

Jardiance (Empagliflozin) at a Glance

Unlike several older glucose-lowering therapies, empagliflozin combines glucose control with low intrinsic hypoglycemia risk, modest weight reduction, and proven heart and kidney benefits.

Compare current Jardiance and empagliflozin prices. Prices, prescription rules, and product availability differ by country, and an overseas generic is not automatically approved for the U.S. market.

What Made Empagliflozin Different From Many Older Diabetes Medicines?

Empagliflozin arrived during an important change in diabetes care. For many years, glucose-lowering medicines were judged mainly by their effect on HbA1c. Cardiovascular outcome trials later showed that the choice of treatment could also influence hospitalization for heart failure, cardiovascular death, and progression of kidney disease.

That broader clinical role is what made SGLT2 inhibitors distinctive. Jardiance is not universally better than every older diabetes medicine: metformin remains useful and inexpensive, sulfonylureas can lower glucose effectively, and insulin is indispensable in many situations. Empagliflozin offers a different balance of glucose control, weight effects, hypoglycemia risk, and cardiorenal protection.

Low Intrinsic Hypoglycemia Risk

Empagliflozin does not primarily lower glucose by stimulating pancreatic beta cells to release insulin. Instead, it changes how the kidneys handle filtered glucose. In adult monotherapy trials, hypoglycemia rates were low and similar to placebo.

The risk rises when Jardiance is combined with insulin or an insulin secretagogue such as a sulfonylurea. Pediatric trial data also showed more hypoglycemia with empagliflozin than placebo, including among some children who were not using insulin. Age, food intake, kidney function, treatment combinations, and other clinical factors all influence the individual risk.

Weight Profile

Insulin, sulfonylureas, and some other glucose-lowering treatments can contribute to weight gain. Empagliflozin usually has the opposite effect because glucose and its energy content are lost in urine. Average weight reduction is generally modest rather than dramatic.

Jardiance is not an obesity medicine and does not produce weight reductions comparable with therapies specifically approved for chronic weight management. Its effect on weight is best understood as a secondary metabolic feature of SGLT2 inhibition.

Cardiovascular Benefit

Cardiovascular outcome data changed the way clinicians viewed empagliflozin. The goal was no longer limited to lowering HbA1c: in adults with type 2 diabetes and established cardiovascular disease, treatment also reduced cardiovascular death. Dedicated cardiovascular evidence is discussed in detail later in this article.

Heart-Failure Benefit

Empagliflozin subsequently demonstrated benefits in chronic heart failure across reduced and preserved ejection fraction. That was an important shift. Clinicians were no longer using it simply as a diabetes medicine, but specifically because of its effects on heart-failure outcomes, including in people without diabetes.

Kidney Protection

SGLT2 inhibition can reduce pressure within the kidney’s filtering units and slow long-term loss of kidney function in appropriate patients. Empagliflozin now has an established role in chronic kidney disease, again including some patients who do not have diabetes.

Insulin-Independent Action

Because empagliflozin works through the kidneys rather than by forcing insulin secretion, it can lower glucose in the presence of insulin resistance. Its direct glucose-lowering effect becomes weaker as kidney filtration declines, although its heart and kidney benefits may remain clinically relevant at levels of renal function where the HbA1c effect is limited.

Jardiance Compared With Several Older Glucose-Lowering Approaches

The table highlights broad differences rather than ranking treatments. Metformin and sulfonylureas are usually much less expensive, while insulin can lower glucose when oral medicines are insufficient and remains essential in type 1 diabetes. Treatment choice depends on glycemic needs, cardiovascular and kidney conditions, adverse-effect risks, cost, and the individual treatment plan.

How Jardiance Works

The kidneys continually filter the blood. Glucose enters the initial filtrate and is normally reclaimed before urine leaves the kidney. Most of this reabsorption is handled by sodium-glucose cotransporter 2, a protein located in the proximal renal tubule.

Empagliflozin inhibits SGLT2. As a result, the kidneys return less filtered glucose to the circulation and allow more of it to pass into the urine. Urinary glucose excretion rises after the first dose and continues with once-daily treatment, lowering both fasting and post-meal glucose in people with type 2 diabetes.

The amount of glucose removed is not constant. It depends partly on the glucose concentration in the blood and the amount of blood being filtered by the kidneys. Higher blood glucose means more glucose is available for excretion. When glomerular filtration falls substantially, less glucose reaches the renal tubules, so empagliflozin has less effect on HbA1c.

SGLT2 also transports sodium. Blocking it sends more sodium farther along the nephron, where the kidney uses that signal to adjust pressure inside the glomerulus. This process, known as tubuloglomerular feedback, can reduce abnormally high pressure within the kidney’s filtering units.

An early, usually modest drop in estimated glomerular filtration rate, or eGFR, may appear after treatment begins. The value often stabilizes, after which kidney function can decline more slowly than it would without treatment. This pattern differs from steadily progressive kidney injury, although renal function still needs to be assessed in the appropriate clinical context.

The heart-failure effects are probably produced by several connected changes. Empagliflozin promotes mild osmotic diuresis and sodium loss, which can reduce circulatory congestion and the workload on the heart. Changes in kidney pressure, blood pressure, vascular function, and cardiorenal signaling may also contribute. The benefits seen in people without diabetes show that glucose lowering is only part of the explanation.

Readers looking for more detail can review this overview of recent SGLT2 inhibitor research.

Current FDA-Approved Uses of Jardiance

According to the current U.S. prescribing information, Jardiance is indicated for the following purposes:

• To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
• To reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression.
• To reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
• As an adjunct to diet and exercise to improve glycemic control in adults and children aged 10 years and older with type 2 diabetes.

These are separate indications. A patient does not need to have all of these conditions to be prescribed empagliflozin. Someone without diabetes, for example, may receive Jardiance for heart failure or chronic kidney disease.

Jardiance is not FDA-approved to improve glycemic control in type 1 diabetes. SGLT2 inhibitors substantially increase the risk of diabetic ketoacidosis in that population, and fatal cases have occurred. The medicine is also not approved as a weight-loss treatment.

Jardiance Dosage and Strengths

Jardiance is available as 10 mg and 25 mg film-coated tablets. The labeled adult dose for heart failure, chronic kidney disease, and cardiovascular risk reduction is 10 mg once daily. For glycemic control in type 2 diabetes, treatment generally begins with 10 mg once daily and may be increased to 25 mg if the lower dose is tolerated and additional glucose reduction is needed.

The 25 mg strength is used to increase the glycemic effect. It has not been shown to provide a greater heart-failure or kidney-outcome benefit than the standard 10 mg dose used for those indications.

Tablets are taken in the morning with or without food. Additional information is available in this guide to Jardiance dosing.

Renal function and volume status should be assessed before treatment and monitored when clinically appropriate. The FDA label recommends withholding Jardiance for at least three days, when possible, before surgery or a procedure associated with prolonged fasting. Treatment is generally resumed after the patient is clinically stable and has restarted oral intake, following the clinician’s instructions.

Pediatric Use

Jardiance is FDA-approved to improve glycemic control in children aged 10 years and older with type 2 diabetes. It has not been established as a pediatric treatment for heart failure, chronic kidney disease, or cardiovascular risk reduction. Safety and effectiveness for glycemic control have not been established in children younger than 10.

Jardiance Timeline: From Diabetes Drug to Cardiorenal Therapy

Jardiance for Type 2 Diabetes: Benefits and Limitations

For type 2 diabetes, Jardiance may be used alone or together with other glucose-lowering medicines, depending on glycemic needs, cardiovascular and kidney conditions, tolerability, and the treatment plan. Possible combinations include metformin, insulin, a sulfonylurea, a DPP-4 inhibitor, a GLP-1 receptor agonist, or other appropriate therapy.

In adult clinical trials, empagliflozin reduced HbA1c, fasting plasma glucose, and body weight compared with placebo. The size of the HbA1c reduction depends partly on the starting glucose level and kidney function. A person beginning treatment with a higher HbA1c may see a larger numerical change than someone already close to an individualized target.

The glucose-lowering effect becomes weaker as eGFR declines. The current FDA label does not recommend Jardiance specifically for glycemic control in type 2 diabetes when eGFR is below 30 mL/min/1.73 m², because it is unlikely to provide enough glucose reduction at that level of filtration.

Its heart and kidney indications are a different matter. Empagliflozin may still have cardiorenal value in selected patients whose kidney function is too low for a strong HbA1c effect. This is one reason the clinical purpose of the prescription must be clear.

Jardiance does not replace nutrition, physical activity, glucose monitoring, or treatment of blood pressure and cholesterol. It also does not replace insulin when insulin is medically necessary.

Cardiovascular Benefits of Empagliflozin

The 2015 EMPA-REG OUTCOME trial studied more than 7,000 adults with type 2 diabetes and established cardiovascular disease. Participants received empagliflozin or placebo in addition to standard care.

Empagliflozin reduced the relative risk of the primary composite cardiovascular outcome by 14%. The study also found a 38% relative reduction in cardiovascular death and a 35% relative reduction in hospitalization for heart failure. These percentages describe a high-risk population that already had cardiovascular disease, not every person with type 2 diabetes.

The findings broadened the purpose of glucose-lowering treatment. A medicine could be selected not only for its effect on HbA1c but also because it had demonstrated an effect on cardiovascular outcomes.

Current American Diabetes Association guidance gives cardiovascular and kidney conditions a central role in treatment selection. For people with established cardiovascular disease, heart failure, or chronic kidney disease, the choice of medication may be influenced by outcome evidence even when HbA1c is near the individualized target.

Why Jardiance Is Used for Heart Failure

Heart failure develops when the heart cannot fill or pump efficiently enough to meet the body’s needs without elevated filling pressure. It can occur with reduced ejection fraction, preserved ejection fraction, or values between those categories. Diabetes increases the risk, but many people with heart failure do not have diabetes.

Heart Failure With Reduced Ejection Fraction

EMPEROR-Reduced studied adults with symptomatic heart failure and an ejection fraction of 40% or lower. Participants were already receiving recommended heart-failure treatment.

Over a median of 16 months, cardiovascular death or hospitalization for heart failure occurred in 19.4% of the empagliflozin group and 24.7% of the placebo group. The difference was driven largely by fewer heart-failure hospitalizations, and the benefit was present in participants with and without diabetes.

Heart Failure With Preserved Ejection Fraction

EMPEROR-Preserved extended the evidence to adults whose ejection fraction was above 40%. The primary outcome occurred in 13.8% of participants receiving empagliflozin and 17.1% receiving placebo.

Here, too, the main effect was fewer hospitalizations for heart failure. The trial did not show a clear reduction in cardiovascular death as an individual outcome, but it addressed an area where effective treatment options had historically been limited.

Empagliflozin is normally one part of a broader heart-failure regimen. Depending on the type of heart failure and the patient’s condition, treatment may also include an angiotensin receptor-neprilysin inhibitor, ACE inhibitor, angiotensin receptor blocker, evidence-based beta blocker, mineralocorticoid receptor antagonist, diuretic, or other therapy.

Why Jardiance Is Used for Chronic Kidney Disease

Chronic kidney disease is defined by persistent structural kidney damage or reduced kidney function. Diabetes is a common cause, but CKD can also result from hypertension, vascular disease, glomerular disorders, and other conditions.

The EMPA-KIDNEY trial enrolled 6,609 adults with CKD. Some had diabetes and some did not. Participants generally had an eGFR from 20 to below 45 mL/min/1.73 m², or a higher eGFR combined with significant albuminuria.

Kidney-disease progression or cardiovascular death occurred in 13.1% of the empagliflozin group and 16.9% of the placebo group. The results showed that kidney protection was not limited to diabetic kidney disease and supported a broader role for empagliflozin in adults at risk of CKD progression.

The FDA indication covers reduction of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization. Jardiance is not recommended by the U.S. label for treating CKD in people with polycystic kidney disease or those requiring certain intravenous immunosuppressive therapies or high-dose corticosteroids for kidney disease. These groups were excluded from the pivotal trial.

The KDIGO chronic kidney disease guideline places SGLT2 inhibitors among the main kidney-protective therapies for appropriate patients. Renal function, albuminuria, blood pressure, volume status, and other medications still shape the individual decision.

Jardiance and Weight Loss

Jardiance can produce modest weight reduction, particularly in people being treated for type 2 diabetes. In several adult glycemic-control trials, average body weight fell by approximately 2% to 3% over about 24 weeks, although results varied with background therapy and the characteristics of the study population.

Urinary glucose carries calories out of the body. Mild osmotic diuresis can also contribute to the initial change on the scale. Over time, appetite and metabolic adaptations may offset part of this energy loss, which helps explain why weight reduction usually remains limited.

Preclinical and Human Evidence

Preclinical studies have explored whether empagliflozin affects energy expenditure, adipose tissue, liver fat, and inflammatory signaling. Much of the detailed work involving brown fat, macrophage polarization, and related metabolic pathways comes from animal models.

Those findings help researchers investigate possible mechanisms, but human outcomes must be judged from human clinical trials. Randomized trials in people with type 2 diabetes show modest average weight reduction rather than the large losses associated with medicines specifically developed for obesity.

Jardiance is not FDA-approved as a weight-loss treatment. It should not be presented as an alternative to modern GLP-1 or GLP-1/GIP therapies that have specific obesity indications and separate outcome evidence.

Use in People Without Diabetes

Empagliflozin has a low intrinsic hypoglycemia risk in adults because it does not force the pancreas to release insulin. Severe hypoglycemia is therefore not the expected result when an adult without diabetes receives the medicine for an approved heart-failure or kidney indication.

Low hypoglycemia risk does not make unsupervised use appropriate. Empagliflozin can cause dehydration, low blood pressure, genital infections, urinary infections, kidney-function changes, and ketoacidosis. Ketoacidosis has occurred with only moderately elevated glucose and has also been reported in people without diabetes taking SGLT2 inhibitors for heart or kidney conditions.

Jardiance Side Effects and Safety

The overall safety profile is similar across the type 2 diabetes, heart-failure, and chronic-kidney-disease programs, although individual risk varies with age, kidney function, other medication, volume status, and the reason for treatment.

Common or Expected Effects

Genital mycotic infections. Glucose in the urine creates conditions that can favor yeast growth. Vulvovaginal candidiasis, balanitis, and related fungal infections occur more often with empagliflozin than placebo. Symptoms can include itching, redness, swelling, discharge, or discomfort. A history of recurrent genital infection increases the likelihood of another episode.

Urinary tract infections. UTIs were common in clinical trials, especially among women and people with a history of chronic or recurrent infection. Most are uncomplicated, but urinary symptoms should be assessed rather than assumed to be a harmless effect of treatment.

Increased urination and thirst. Empagliflozin increases urinary glucose and produces mild osmotic diuresis. Some people notice more frequent urination, nocturia, or increased thirst, particularly after beginning treatment.

Volume depletion and lower blood pressure. Fluid loss can cause dizziness, weakness, orthostatic symptoms, or a temporary change in creatinine. The risk is higher in older adults, people with impaired renal function, those taking loop diuretics, and patients who already have low blood pressure.

Hypoglycemia with combination therapy. In adult monotherapy trials, hypoglycemia rates were low and similar to placebo. The risk increases when Jardiance is combined with insulin or a sulfonylurea. A clinician may adjust the dose of the accompanying medicine, but patients should not make those changes independently.

Less Common but Important Warning Signs

Ketoacidosis. SGLT2 inhibitors can cause diabetic ketoacidosis or other forms of ketoacidosis, sometimes with blood glucose below 250 mg/dL. Warning symptoms include nausea, vomiting, abdominal pain, unusual fatigue, difficulty breathing, and generalized illness.

Common precipitating factors include missed or sharply reduced insulin, acute illness, prolonged fasting, surgery, dehydration, pancreatic disorders, ketogenic diets, and heavy alcohol use. Compatible symptoms require assessment even when the glucose reading is not extremely high.

Serious urinary infections. Pyelonephritis and urosepsis have been reported. Fever, flank pain, vomiting, blood in the urine, or rapidly worsening urinary symptoms warrant prompt medical attention.

Fournier’s gangrene. Necrotizing fasciitis of the perineum is rare but potentially life-threatening. Pain, tenderness, redness, or swelling in the genital or perineal area accompanied by fever or malaise requires urgent evaluation.

Acute kidney injury. A modest early eGFR dip can be part of the expected hemodynamic response, but acute kidney injury has also been reported after marketing. Dehydration, acute illness, diuretics, and reduced circulating volume can increase the risk.

Hypersensitivity reactions. Rash, urticaria, and angioedema have been reported. Swelling of the face, lips, tongue, or throat requires urgent care.

Lower-Limb and Foot Considerations

The current U.S. label includes a warning about lower-limb amputation observations in SGLT2 outcome trials. Across four Jardiance outcome trials, overall event rates were similar between pooled Jardiance and placebo groups, although an imbalance appeared in the CKD trial.

Baseline risk is higher in people with peripheral arterial disease, previous amputation, diabetic foot disease, ulcers, osteomyelitis, or active infection. Routine foot care and early evaluation of new sores, discoloration, pain, or tenderness are particularly important for these patients.

Laboratory Changes

A small early increase in creatinine or decrease in eGFR may occur before kidney function stabilizes. The label also describes modest increases in LDL cholesterol and hematocrit. These findings are interpreted alongside the patient’s broader cardiovascular, renal, and hematologic status.

Who Should Not Take Jardiance or Needs Additional Assessment?

The formal U.S. contraindication is serious hypersensitivity to empagliflozin or an ingredient in Jardiance. Several other situations require avoidance, temporary interruption, or closer assessment.

• Type 1 diabetes: Jardiance is not approved for glycemic control because of the increased ketoacidosis risk.
• Previous ketoacidosis or high current risk: The cause, insulin status, diet, illness, alcohol use, and pancreatic history need review.
• Acute illness or prolonged fasting: Temporary interruption may be needed.
• Surgery: The FDA label recommends withholding Jardiance for at least three days beforehand when possible.
• Volume depletion or low blood pressure: Fluid status should be corrected before treatment begins.
• Dialysis or very advanced kidney disease: Pivotal outcome trials did not enroll patients already receiving dialysis or those with an eGFR below 20 mL/min/1.73 m² at enrollment.
• Pregnancy: Jardiance is not recommended during the second and third trimesters because of potential effects on the developing fetal kidney.
• Breastfeeding: The U.S. label advises against use because of possible risk to postnatal kidney development.
• Recurrent genital or urinary infections: Previous frequency and severity should be considered.
• Diabetic foot disease or peripheral arterial disease: Preventive foot care and monitoring are especially important.

Important Interactions

• Diuretics: The combination can increase urine volume and the risk of dehydration or hypotension.
• Insulin and insulin secretagogues: These combinations increase hypoglycemia risk.
• Lithium: SGLT2 inhibitors can increase renal lithium excretion and lower blood lithium concentrations, making additional monitoring necessary in some patients.
• Urine glucose tests: Positive urine glucose is expected and should not be used to judge glycemic control during treatment.
• 1,5-anhydroglucitol testing: The 1,5-AG assay is unreliable in people taking an SGLT2 inhibitor.

Jardiance Generic: Is Generic Empagliflozin Available?

What Is the Generic Name of Jardiance?

The generic name for Jardiance is empagliflozin. Jardiance identifies Boehringer Ingelheim’s original branded product. Generic empagliflozin identifies products made by other manufacturers and approved through the regulatory system of the country where they are sold.

A package labeled “empagliflozin” is therefore not automatically a U.S.-approved generic. Regulatory approvals are territorial: an Indian or European authorization does not constitute FDA approval.

Is Generic Jardiance Currently Available in the United States?

No generic empagliflozin equivalent of Jardiance is currently marketed in the United States. However, the regulatory history is more complicated than a simple statement that the FDA has never approved one.

On August 3, 2022, the FDA granted Zydus Pharmaceuticals final approval for empagliflozin 10 mg and 25 mg tablets as the first generic of Jardiance. The application demonstrated bioequivalence to the reference product and received an AB therapeutic-equivalence rating at approval.

The current Drugs@FDA record for ANDA 212138 lists both the 10 mg and 25 mg strengths as discontinued. In FDA drug databases, that marketing status can include a product that was never commercially launched as well as one that was marketed and later withdrawn. It does not imply that the approval was removed for a safety or effectiveness problem.

Brand-name Jardiance remains commercially available. With the Zydus products in the discontinued list, U.S. patients do not currently have a marketed generic equivalent to fill at a pharmacy.

What Do Tentative Generic Approvals Mean?

Other manufacturers have received tentative FDA approval for empagliflozin tablets. Examples include applications from Annora Pharma and Sun Pharmaceutical.

Tentative approval means the FDA found that the application met substantial scientific requirements, including bioequivalence, at the time of review, but could not grant final approval because of patent protection, exclusivity, or another blocking issue. A tentatively approved product cannot be marketed under that approval until the remaining conditions are resolved and the FDA grants final approval.

The practical answer for consumers is straightforward: the FDA approved a Zydus generic in 2022, but it is now listed as discontinued; other applications remain in the pipeline; and no generic Jardiance equivalent is currently sold in the United States.

Generic Empagliflozin in India

India illustrates the difference between a drug’s generic name and genuine generic-market competition. Empagliflozin was always the generic name of Jardiance, but broad multi-manufacturer availability expanded after the principal Indian patent expired on March 11, 2025.

Manufacturers responded quickly. In April 2025, the Economic Times reported that 71 new brands from 17 companies had appeared within about a month. Early participants included Mankind Pharma, Glenmark, Alkem, and other established Indian manufacturers.

The influx produced intense price competition. A March 2025 market report described some introductory prices falling from around ₹60 to approximately ₹5.50 per tablet. That figure captures the immediate market disruption rather than a permanent nationwide price for every strength, manufacturer, and pharmacy.

Many Indian generics are sold under brand-like trade names rather than simply as “empagliflozin tablets.” This is commonly described as a branded-generic market. The product’s manufacturer, strength, registration, excipients, and supply chain still need to be checked.

Why Availability Differs by Country

A generic can reach one market years before another. Patent and exclusivity periods vary, and each manufacturer must submit an application to the local regulator. Approval is followed by a separate commercial decision: a company may postpone launch because of patent settlements, manufacturing plans, pricing, or expected demand.

Generic approval also applies to a defined manufacturer, product, strength, and jurisdiction. A product approved in India cannot be marketed as an FDA-approved U.S. generic unless the FDA has separately approved that product and it is legally placed into U.S. distribution.

Jardiance Versus Generic Empagliflozin

A regulator-approved generic is expected to deliver the same active ingredient at a bioequivalent rate and extent. Tablet color, shape, markings, and inactive ingredients may differ. Excipients can matter to people with specific allergies or intolerances, even when they do not change the medicine’s expected therapeutic effect.

Online product listings require additional care. The words “generic Jardiance” do not establish that a seller is licensed, the product is genuine, or the medicine is approved in the buyer’s country.

Generic Empagliflozin Availability by Market

The contrast is useful: the United States has a past final generic approval without a currently marketed product, while India has active competition among numerous manufacturers. Marketed availability, rather than the generic name alone, determines whether a patient can actually obtain a lower-cost alternative.

Jardiance Cost, Insurance, and Access

Brand Jardiance Cost in the United States

Jardiance remains a brand-dominated medicine in the United States, which helps explain its high cash price. The amount paid at the pharmacy varies according to insurance coverage, deductible, formulary tier, coinsurance, pharmacy network, prescription quantity, and eligibility for assistance.

A manufacturer list price is not the same as the patient’s out-of-pocket cost or the net price after rebates. Fixed monthly figures also become outdated quickly. Patients comparing options should check the current cash price, their plan’s cost-sharing amount, and any legitimate assistance for which they qualify.

Medicare Part D in 2026

Jardiance was included in the first group of medicines negotiated under the Medicare Drug Price Negotiation Program. Beginning January 1, 2026, CMS established a maximum fair price of $197 for a 30-day equivalent supply.

That figure is used within the Medicare program; it is not a universal pharmacy copayment. What an individual pays still depends on the plan’s deductible, tier, copayment or coinsurance, pharmacy, and benefit stage.

In 2026, the maximum Medicare Part D deductible is $615, and annual out-of-pocket spending for covered Part D medicines is capped at $2,100. After qualifying spending reaches the cap, the beneficiary generally pays no further copayment or coinsurance for covered Part D medicines during the rest of that calendar year.

People with limited income and resources may qualify for Medicare Extra Help. Formularies can also apply prior authorization or other utilization-management requirements, so coverage details should be checked with the individual plan.

Commercial Insurance and the Jardiance Savings Card

The manufacturer offers a U.S. Jardiance Savings Card. Eligible patients may pay as little as the amount stated in the current offer for a 30- to 90-day prescription, subject to maximum benefits and program terms.

The card is intended for qualifying commercially insured patients. It cannot be used when the prescription is paid in whole or in part by Medicare, Medicaid, Medigap, Veterans Affairs, Department of Defense, TRICARE, or another specified government program. It is a U.S. program and should not be described as a worldwide coupon accepted by international pharmacies.

Patient Assistance

The Boehringer Cares Patient Assistance Program can provide eligible medicines free of charge to qualifying U.S. patients. Residence, income, insurance, and other requirements apply. Patient assistance and commercial copay cards are separate programs with different eligibility rules.

Coupons and Pharmacy Discount Programs

Independent pharmacy coupons may reduce a cash price, but they are not insurance. A discounted purchase may not count toward an insurance deductible or the Medicare Part D out-of-pocket limit. The useful comparison is the final amount due at the pharmacy, not the advertised percentage discount.

Generic Empagliflozin Prices Outside the United States

Generic empagliflozin usually costs less in countries with several competing manufacturers. India’s sharp price reductions after March 2025 reflected the end of local patent protection, rapid launches, domestic manufacturing, and strong competition in an out-of-pocket pharmaceutical market.

International prices vary with strength, pack size, manufacturer, national price controls, reimbursement, currency, taxes, and pharmacy margins. An Indian tablet price cannot be converted into a universal generic Jardiance price for another country.

Overseas purchasing also raises questions beyond cost: whether personal importation is lawful, whether a prescription is required, whether the pharmacy is licensed, whether the product is approved, and whether the supply chain protects against falsified or improperly stored medicine.

Frequently Asked Questions

What is the generic name for Jardiance?

The generic name and active ingredient of Jardiance is empagliflozin. It belongs to the SGLT2 inhibitor class.

Is there a generic for Jardiance?

It depends on the country. India has many marketed generic and branded-generic products. The FDA approved a Zydus generic in 2022, but it is now listed as discontinued and no generic equivalent is currently marketed in the United States.

Has the FDA ever approved generic Jardiance?

Yes. Zydus Pharmaceuticals received final FDA approval for empagliflozin 10 mg and 25 mg tablets on August 3, 2022. The current Drugs@FDA record lists both strengths as discontinued.

Is empagliflozin the same as Jardiance?

Empagliflozin is the active medicine in Jardiance. A regulator-approved generic contains the same active ingredient, but its manufacturer, appearance, inactive ingredients, packaging, price, and country-specific approval can differ.

Is generic Jardiance currently available in the United States?

No marketed generic equivalent was identified as of August 2026. The previously approved Zydus products are listed as discontinued, while several other applications have tentative rather than final approval.

What is tentative FDA approval?

It means a generic application has met substantial scientific requirements but cannot yet receive final approval, usually because of patent or exclusivity restrictions. Tentative approval does not allow the product to be marketed.

Why is Jardiance expensive?

The U.S. market lacks active generic competition. Brand pricing, insurer negotiations, rebates, formulary placement, and the pharmacy supply chain all influence the final cost.

Is generic empagliflozin cheaper?

Usually, especially in countries with multiple manufacturers. The actual difference varies by market, strength, manufacturer, reimbursement system, and pharmacy.

What strengths does Jardiance come in?

Jardiance is available as 10 mg and 25 mg tablets. The 10 mg dose is used for the labeled heart-failure and CKD indications. For type 2 diabetes, the dose may be increased to 25 mg when additional glycemic control is needed and 10 mg is tolerated.

What makes Jardiance different from older diabetes medicines?

It lowers glucose through an insulin-independent kidney mechanism, has low intrinsic hypoglycemia risk in adults when used without insulin or an insulin secretagogue, and has established heart-failure and kidney benefits.

Does Jardiance cause hypoglycemia?

Hypoglycemia is uncommon during adult monotherapy. The risk rises when Jardiance is combined with insulin or an insulin secretagogue such as a sulfonylurea. Pediatric trial data also showed a higher rate with empagliflozin than placebo.

Does Jardiance cause weight loss?

It can cause modest average weight reduction, particularly in people with type 2 diabetes. It is not approved as a weight-loss medicine and should not be compared with therapies developed specifically for obesity.

Why is Jardiance used for heart failure?

Clinical trials found fewer cardiovascular deaths or heart-failure hospitalizations with empagliflozin, with much of the benefit coming from fewer hospitalizations. Benefits occurred across reduced and preserved ejection fraction and in people with or without diabetes.

Why is Jardiance used for kidney disease?

Empagliflozin can reduce pressure inside the kidney’s filtering units and slow long-term loss of kidney function. EMPA-KIDNEY showed a lower risk of kidney-disease progression or cardiovascular death in a broad CKD population.

Can Jardiance be used without diabetes?

Yes. Adults may receive Jardiance for an approved heart-failure or chronic-kidney-disease indication even if they do not have diabetes. It is not intended for unsupervised weight loss or general prevention.

Is Jardiance used for type 1 diabetes?

No. Jardiance is not FDA-approved to improve glycemic control in type 1 diabetes because SGLT2 inhibitors substantially increase the risk of diabetic ketoacidosis in that population.

Are Indian empagliflozin products FDA-approved?

Not unless the FDA has separately approved the specific product and manufacturer for the United States. Indian authorization and FDA approval are different regulatory statuses.

Conclusion

Jardiance is the original brand of empagliflozin, an SGLT2 inhibitor used for type 2 diabetes and selected cardiovascular and kidney indications. Its clinical importance extends beyond HbA1c: empagliflozin has demonstrated benefits in adults with heart failure, chronic kidney disease, and type 2 diabetes with established cardiovascular disease.

The phrase “Jardiance generic” can refer either to the drug’s generic name or to a lower-cost commercial product. Empagliflozin is the generic name in every market. Actual generic availability depends on local patents, regulatory approval, and commercial launch.

The United States presents an unusual case. FDA granted first-generic approval to Zydus in 2022, but both strengths are now listed as discontinued and no generic equivalent is currently marketed. Other applications have tentative approval. India, meanwhile, developed extensive multi-manufacturer competition after the March 2025 patent expiry.

Brand and properly approved generic products contain the same active medicine, but approval cannot be transferred from one country to another. The appropriate indication, dose, kidney function, interacting medicines, safety risks, and available cost support should be reviewed with a qualified healthcare professional.

Medical, regulatory, generic-availability, and pricing information reviewed for August 2026. These details may change.